Patient Blood Management Market

The Patient Blood Management Market is valued at USD 15.9 Bn in 2026 and is projected to reach USD 25.2 Bn,  growing at a CAGR of 7% by 2033.

A patient blood management program includes the identification of the most effective treatment regimen for each patient based on various lab tests, and inventory control strategy that minimizes wastage and allows for improved inventory security, and a training program that educates healthcare professionals on best practices. In addition, many hospitals have implemented guidelines that dictate proper treatment protocols when administering transfusions or performing invasive procedures such as endoscopies or dialysis. However, lack of awareness about PBM among medical personnel may act as a restraining factor for this market.

Blood transfusion remains the mainstay in-patient care; however, with blood availability and disease treatment changing rapidly, there is a need to learn how to conserve these resources. A resource is "conserved" when it has a less negative influence on morbidity or mortality than previously expected. Wherein, the demand for Patient Blood Management (PBM) is increasing rapidly as it aims at reducing perioperative blood loss through the appropriate use of diagnostic tests and specific medical devices, minimizing intraoperative blood transfusion by using autologous blood products whenever possible, standardizing their use, and optimizing postoperative intravenous fluid management. The most important measure for PBM is strict adherence to evidence-based guidelines. Optimization of anemia correction in compromised patients is also key in achieving good clinical outcomes. Most of these practices will also reduce costs and potentially decrease the number of allogenic blood donors, thus reducing donor exposure to risks.

Following are some of the key factors driving the demand for patient blood management services

• Decreased post-operative morbidity
• Improved quality of life for those with chronic diseases
• Decreased mortality rates from some diseases that are associated with high surgical risk
• Decreased donor exposure to infectious disease

Patient Blood Management is a recent evolution of guidelines aimed at preserving patients' health as well as the nation's blood resources. It aims to preserve these resources by reducing or eliminating autologous transfusions where possible, thereby decreasing costs and potentially leading to a reduction in the number of donors needed on a yearly basis. Evidence-based guidelines provide a mechanism to assist physicians in achieving these goals, as well as avoid the pitfalls that could be associated with treatment decisions that are not supported by evidence or best practices.

Proactive approach from leading healthcare institutes to fuel the demand for patient blood management

Patient Blood Management can also help the healthcare system to better address the growing problem of anemia, which is responsible for one out of every five deaths worldwide and accounts for almost half of all visits made by patients to general practitioners each year. Anemia predicts poor outcomes for many diseases and conditions, including heart failure, chronic obstructive pulmonary disease (COPD), kidney disease, cancer, stroke, and autoimmune disorders such as rheumatoid arthritis. The Canadian Hematology Society recognizes PBM treatment guidelines as effective means to reduce unnecessary blood transfusions and optimize hemoglobin care for patients with chronic diseases.

The American College of Critical Care Medicine (ACCM) has endorsed PBM, saying "transfusion of allogeneic blood products should be viewed as a therapeutic intervention intended to achieve hemostasis and the goals of therapy must be achieved without exposing patients to increased risk or harm." The Canadian Medical Association Journal said that PBM is a "quality improvement initiative," not a "bloodless medicine" approach. In Europe, the European Association for Haematology recommends that patients on oral antithrombotic drugs receive an initial test dose of vitamin K antagonist at every hospitalization where adequate monitoring is available. They have further recommended that on oral anticoagulant therapy, the international normalized ratio (INR) should be monitored quarterly.

As well as receiving support from professional organizations worldwide, PBM has also been endorsed by national patient groups in Norway and the United States.

Patient Blood Management is currently being applied toward a variety of medical conditions with different degrees of success

• Cancer patients - prescribing oral anticoagulants without requiring INR monitoring can decrease allogeneic transfusions and potentially decrease bleeding complications associated with treatment
• Post-CABG patients - those who receive at least two units of blood have increased hospital mortality rates, regardless of whether they also received perioperative antibiotics or an internal mammary artery graft
• Hip fracture patients - hemoglobin levels of 10 g/dL at the time of surgery is associated with increased mortality rates
• Patients in intensive care units (ICU) - using restrictive transfusion thresholds is associated with decreased mortality rates. The use of perioperative autologous blood salvage techniques has also been shown to decrease mortality rates and hospital stays
• Gastric bypass surgery patients - requiring a FFP:RBC ratio >1 has not been found to affect post-surgery outcomes. Future studies should compare the costs and effectiveness of restrictive versus liberal transfusion thresholds in this high-risk patient population

Blood banks to remain the largest end-user of patient blood management market

About 10 percent of patients who receive blood transfusions in the hospital are given blood that was donated by another person rather than manufactured by a blood bank. Blood banks, therefore, are the largest users of patient blood management (PBM), using methods to acquire and process more than 14 million units of red blood cells for transfusion every year in the US. Blood banks also collect about 2 million units of platelets each year; for this reason, some experts believe PBM techniques will eventually be used primarily with platelets.

Blood banks--which are a collection of organizations that collect, process and distribute blood to hospitals--are pushing for the development of PBM techniques with platelets because platelets have a short shelf life and can be difficult to store. Unlike red blood cells, platelets must be transfused within five days of collection; they also must be stored at refrigerator temperatures between 2 and 8 degrees Celsius (35-46 degrees Fahrenheit). Platelet PBM would allow patients receiving chemotherapy or patients who need surgery to receive more platelets than usual with less risk for complications including febrile response, intracranial hemorrhage, and venous thromboembolism.

Global demographic

In 2015, there were about 108 million blood donations worldwide from 44.7 million voluntary unpaid donors with most of these donors being from high-income countries (57%). In addition, around 27 million units of blood components were donated globally in 2015.  The number has increased to 118.4 million units in 2019. In many cases, donated blood is released for patient use within a few days of collection. However, blood can be stored for up to six weeks and still undergo the process of being made into a product that can be used by another human.

It has been found that high-income countries are the largest contributors to the supply. There are 40% of donors from high-income countries compared to 30% from upper-middle-income countries, 21% from lower middle-income countries, and 9% from low-income countries.

Altogether, 7 out of 10 blood donors are male with approximately 52.7 million male donors, while 41.3 million female donors donated their blood in 2015. These numbers have increased to 27.8 million more selfless men willing to donate compared to 19.6 million women in 2019. The voluntary unpaid donor population has been seen as a strong safety net for the global health system due to its availability and universal coverage across all ages groups and demographic profiles.

North America to continue leading the global market

North American has been witnessing a strong presence of blood management in this region. Many universities, research organizations, and private companies are investing heavily for the development of innovative techniques for effective cross-matching, rapid collection, short storage time, and better compatibility testing technologies. Such kind of movement is evidenced by many factors that include increasing demand for blood transfusion across North America, increased awareness regarding safe transfusion practices amongst professionals coupled with technological advancements in science etcetera.

Apart from this, increased adoption rate of blood management tools especially for hospitals and clinics under their blood bank to offer safe transfusion practices. Major factors which are driving the market growth in North America include - significant increase in the geriatric population base across Canada and Mexico, increasing demand for platelet transfusions, rising demand for cord blood stem cells for transplants coupled with increased awareness regarding safe practices among healthcare professionals’ etcetera. The other prominent factors which are expected to impact this market growth is a rise in demand for artificial blood substitutes and a significant increase in blood transfusion practices. Further, healthcare institutions such as hospitals & clinics under their blood banks, research organizations, universities, and private companies play the main role of demand drivers for this region.

Key Players

• Haemonetics Corporation
• Fresenius Kabi
• Terumo Corporation
• Grifols, S.A.
• World Courier / AmerisourceBergen
• Cerner Corporation (Oracle Health)
• Siemens Healthineers
• Abbott Laboratories
• Baxter International Inc.
• GE Healthcare
• Medtronic plc
• Stryker Corporation
• Mobius Imaging, LLC
• Pentec Health, Inc.
• Haemokinesis, Inc.

Global Patient Blood Management Market Segmentation 

By Product

• Instruments
  • Blood Processing Devices
  • Blood Transfusion Devices
  • Blood Culture Screening Devices
  • Diagnostic & Testing Instruments
  • Blood Storage Devices
• Accessories
  • Syringes & Needles
  • Vials & Tubes
  • Blood Bags
  • Other Accessories
• Reagents and Kits
  • Culture Media
  • Blood Typing Reagents
  • Slide Staining
  • Assay Kits
  • Others
• Software
  • Blood Bank and Transfusion Software
  • Others

By Component

• Whole Blood
• Blood Components

By End User

• Hospitals
• Blood Banks

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa